Objective.Psychotic symptoms are seen in numerous psychiatric illnesses afflicting the elderly. This article reviews the efficacy of the pharmacologic management of psychotic symptoms in primary psychotic disorders, affective disorders, and neurodegenerative disorders. Method.A comprehensive literature review. Results.Evidence to support the use of pharmacologic interventions to manage psychotic symptoms in elderly patients afflicted with primary psychotic disorders and affective disorders is limited by the absence of randomized, placebo-controlled trials (RCTs). The use of low-dose clozapine is supported by RCTs in Parkinson’s disease. The efficacy of risperidone and olanzapine for the treatment of psychotic symptoms has been demonstrated by large RCTs in Alzheimer’s disease. Conclusion.There is evidence of the efficacy of antipsychotic medications to manage psychotic symptoms in elderly patients. However, the absence of published evidence from RCTs in primary psychotic and affective disorders, and the limited evidence in the neurodegenerative illnesses, is notable.
Get full access to this article
View all access options for this article.
References
1.
1. Targum SD, Abbott JL. Psychoses in the elderly: a spectrum of disorders. J Clin Psychiatry1999; 60:4-10.
2.
2. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry1998; 59:5-12.
3.
3. Östling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry2002; 59:53-59.
4.
4. Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry2000; 8:29-34.
5.
5. Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry2002; 13:21-26.
6.
6. Palmer BW, McClure FS, Jeste DV. Schizophrenia in late life: findings challenge traditional concepts. Harv Rev Psychiatry2001; 9:51-58.
7.
7. Sajatovic M, Perez D, Brescan D, Ramirez LF. Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol Bull1998; 34:819-823.
8.
8. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol2000; 13:28-32.
9.
9. Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Risperidone Working Group. Int J Geriatr Psychiatry2000; 15:506-514.
10.
10. Jeste DV, McClure FS. Psychoses: diagnosis and treatment in the elderly. New Dir Mental Health Serv1997; 53-70.
11.
11. Sajatovic M, Ramirez LF, Garver D, et al. Clozapine therapy for older veterans. Psychiatr Serv1998; 49:340-344.
12.
12. Kiraly SJ, Gibson RE, Ancill RJ, Holliday SG. Risperidone: treatment response in adult and geriatric patients. Int J Psychiatry Med1998; 28:255-263.
13.
13. Madhusoodanan S, Brenner R, Suresh P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry2000; 12:11-18.
14.
14. Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry1999; 7:132-138.
16. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry1992; 149:733-745.
17.
17. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry1999; 60:116-118.
18.
18. Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry1998; 13:23-28.
19.
19. O’Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am J Geriatr Psychiatry2001; 9:382-390.
20.
20. Chen ST, Altshuler LL, Melnyk KA, et al. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. J Clin Psychiatry1999; 60:181-186.
21.
21. Colenda CC. Mania in late life. The challenges of treating older adults. Geriatrics2002; 57:50, 53-54.
22.
22. Sajatovic M. Treatment of bipolar disorder in older adults. Int J Geriatr Psychiatry2002; 17:865-873.
23.
23. McDonald WM. Epidemiology, etiology, and treatment of geriatric mania. J Clin Psychiatry2000; 61:3-11.
24.
24. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson’s disease patients with dementia. J Am Geriatr Soc1996; 44:296-299.
25.
25. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology1993; 43:2227-2229.
26.
26. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol1999; 56:595-601.
27.
27. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J Neural Transm2000; 107:59-71.
28.
28. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Move Disord2000; 15:201-211.
29.
29. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry2002; 52:438-445.
30.
30. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Move Disord2002; 17:1031-1035.
31.
31. Marsh L, Lyketsos C, Reich SG. Olanzapine for the treatment of psychosis in patients with Parkinson’s disease and dementia. Psychosomatics2001; 42:477-481.
32.
32. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci2002; 23:41-43.
33.
33. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol2002; 25:107-110.
34.
34. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin2002; 18:258-264.
35.
35. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Move Disord2001; 16:1171-1174.
36.
36. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J1992; 305:673-678.
37.
37. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology1994; 44:872-877.
38.
38. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47:1113-1124.
39.
39. Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry1999; 14:459-466.
40.
40. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord2002; 13:67-73.
41.
41. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry2000; 15:280-281.
42.
42. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebocontrolled international study. Lancet2000; 356:2031-2036.
43.
43. Gormley N, Rizwan MR. Prevalence and clinical correlates of psychotic symptoms in Alzheimer’s disease. Int J Geriatr Psychiatry1998; 13:410-414.
44.
44. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry1989; 146:577-587.
45.
45. Bassiony MM, Steinberg MS, Warren A, et al. Delusions and hallucinations in Alzheimer’s disease: prevalence and clinical correlates. Int J Geriatr Psychiatry2000; 15:99-107.
46.
46. Forstl H, Burns A, Levy R, Cairns N. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer’s disease. Br J Psychiatry1994; 165:53-59.
47.
47. Levy ML, Cummings JL, Fairbanks LA, et al. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer’s disease. Biol Psychiatry1999; 45:422-425.
48.
48. Rapoport MJ, van Reekum R, Freedman M, et al. Relationship of psychosis to aggression, apathy and function in dementia. Int J Geriatr Psychiatry2001; 16:123-130.
49.
49. Kennedy JS, Zagar A, Bymaster F, et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer’s disease. Int J Geriatr Psychiatry2001; 16:S24-S32.
50.
50. Margallo-Lana M, Swann A, O’Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry2001; 16:39-44.
51.
51. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry1998; 155:1512-1520.
52.
52. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. Risperidone Study Group. J Clin Psychiatry1999; 60:107-115.
53.
53. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology1999; 53:946-955.
54.
54. Brodaty H, Ames D, Snowdon J, et al. A randomised placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry2003; 64:134-143.
55.
55. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry2000; 57:968-976.
56.
56. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer’s dementia. Int J Geriatr Psychiatry2001; 16:S62-S70.
57.
57. Mintzer J, Madhusoodanan S, Brenner R. Risperidone in dementia. Psychiatric Ann2000; 30:181-187.
58.
58. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther2000; 22:1068-1084.
59.
59. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry2002; 159:460-465.
60.
60. Sultzer DL, Gray KF, Gunay I, et al. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc2001; 49:1294-1300.
